![](/img/cover-not-exists.png)
PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS: OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
AJ Batty, GJ Thompson, PA Maroudas, TE DeleaVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72285-9
File:
PDF, 92 KB
english, 2010